Tissue Regenix raises £40m at 16.6% discount
Tissue Regenix Group, the UK regenerative medical technology company owned by IP Group, has issued £40m of shares to finance its acquisition of CellRight Technologies in the US.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts